findmyKOL
Clinical trialNCT02963064TerminatedPhase 1/PHASE2Interventional

JSP191 Antibody Targeting Conditioning in SCID Patients

SponsorJasper Therapeutics, Inc.Enrollment23SCID
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucla Mattel Children'S Hospital

    Los Angeles, California, United States

  • Lucile Packard Children'S Hospital

    Palo Alto, California, United States

  • Ucsf Benioff'S Children'S Hospital

    San Francisco, California, United States

  • Children'S National Medical Center

    Washington D.C., District of Columbia, United States

  • Children'S Healthcare of Atlanta

    Atlanta, Georgia, United States

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, United States

  • University of Minnesota

    Minneapolis, Minnesota, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Cincinnati Children'S Hospital Medical Center

    Cincinnati, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Humanized anti-CD117 Monoclonal Antibody
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Mar 2017
Primary completion
7 Jul 2025
Completion
7 Jul 2025
Last update posted
28 Jul 2025
Registered enrollment
23
Registry id
NCT02963064

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.